Gavin Macbeath, PhD, on Screening for Off-Target Effects

Video

The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.

“Every TCR that we are thinking about introducing into clinical trials will go through SafetyScan, in which we screen it against every possible peptide in the entire human proteome. We comprehensively identify any off targets of the TCR. If a TCR has an off target that's expressed at high levels in a critical organ, we would not move that TCR forward into clinical development. It's a way to vet TCRs and make sure we don't have any off-target effects before we start clinical trials.”

TScan Therapeutics is developing safer T-cell receptor (TCR) therapies with the use of their SafetyScan technology that screens TCRs across all human peptides for a comprehensive view of the therapy’s effects. TScan’s 2 lead programs are targeting leukemia and solid tumor indications with TCR therapies. The leukemia program is heading to phase 1 trials in the coming months.

Gavin Macbeath, PhD, chief scientific officer, TScan Therapeutics, presented data on the company’s programs and the SafetyScan platform at the Onco Cell Therapy Summit (OCTS) USA 2022, held June 29-30 in Boston, Massachusetts.

CGTLive spoke to Macbeath to learn more about the SafetyScan technology and its advantages in reducing toxicities. He also discussed the advantages of TScan’s TCR therapies.

REFERENCE
Macbeath G. Enhanced TCR-T cell therapy for the treatment of hematologic and solid tumor malignancies. Presented at: OCTS USA 2022, June 29-30, Boston, MA.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.